Kamada reported third-quarter 2025 revenues of $47.0 million, up 13% year over year, with adjusted EBITDA up 34% to $11.7 million. Nine-month revenues reached $135.8 million, up 11%, and adjusted EBITDA rose 35% to $34.2 million. The company reiterated full-year guidance of $178–$182 million in revenue and $40–$44 million in adjusted EBITDA, supported by growth in Glassia outside the U.S., higher Varizig sales, and a stronger distribution segment. Operationally, Kamada secured FDA approval for its Houston plasma collection center, initiated an investigator-led post-marketing study of Cytogam in high-risk kidney transplant recipients, and confirmed that an interim futility analysis for its pivotal Phase 3 inhaled alpha-1 antitrypsin program will occur this quarter.
The throughline is intentional integration: a specialty plasma portfolio throwing off cash, a vertically expanding plasma network, and a late-stage respiratory asset that could reshape the company’s mix. The strategic question is whether Kamada is building a durable, cash-generative niche consolidator in hyperimmunes and plasma supply, or positioning for a step-change if inhaled AAT delivers a clinically meaningful and regulator-ready outcome.
This matters now because the plasma industry is recalibrating. Supply constraints from recent years have eased but not disappeared; immunoglobulin demand remains structurally high, and pricing discipline is holding as large players prioritize returns after balance sheet repair. Kamada’s FDA-cleared Houston site, with planned capacity around 50,000 liters per year, adds leverage on the cost of goods and optionality to monetize normal source plasma via long-term offtake agreements. For payers, more stable plasma sourcing could temper volatility in hyperimmune pricing, but the company’s mix skew to specialty indications—rabies exposure, varicella post-exposure prophylaxis, hepatitis B prophylaxis, CMV prevention in transplant—keeps value narratives anchored in targeted, high-acuity use. For competitors, the move signals that smaller, focused operators can expand collection infrastructure and defend margins without the scale of CSL, Takeda, Grifols, or the fast-growing ADMA.
On the Medical Affairs front, the SHIELD study for Cytogam speaks to a critical clinical gap: late CMV after completion of antiviral prophylaxis in transplant. If evidence shows clinically significant reductions in late-onset CMV events or resource utilization, it could reopen payer discussions for immunoglobulin use in defined, high-risk windows and reshape transplant center protocols. Success would require coordinated HCP education, robust real-world data capture, and health-economic modeling that quantifies avoided admissions and graft complications.
The pivotal swing factor remains inhaled AAT. Should the interim assessment support continuation and the full dataset ultimately demonstrate meaningful benefit on pulmonary outcomes with acceptable safety, Kamada could challenge the intravenous augmentation paradigm with a potentially more convenient delivery model. That would expand the company’s addressable market beyond hyperimmunes into chronic respiratory, catalyze ex-U.S. partnerships, and justify increased investment in commercial infrastructure. A negative signal would leave growth anchored to the current portfolio and plasma expansion, still solid but more exposed to plasma pricing cycles and competitive hyperimmune dynamics.
Commercial teams should watch how Kamada allocates its $72 million cash balance and operating cash flow toward in-licensing or M&A, particularly in underserved, guideline-relevant hyperimmune niches where manufacturing know-how is a differentiator. Medical Affairs leaders should prepare for data-driven engagements in transplant and pulmonology that link clinical endpoints to payer-relevant outcomes. The forward test is clear: can Kamada translate operational momentum into evidence that shifts standards of care, or will it remain a disciplined specialist riding the next phase of the plasma cycle?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
